Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sun Pharma, Cadila...

    Sun Pharma, Cadila Healthcare recall products from US market

    Written by supriya kashyap kashyap Published On 2016-12-02T11:15:42+05:30  |  Updated On 2 Dec 2016 11:15 AM IST

    New Delhi : The US-based subsidiaries of two domestic drug firms Sun Pharma and Cadila Healthcare are recalling one product each from the market on account of failure to meet the desired specification norms.


    Zydus Pharmaceuticals USA Inc is recalling 2,472 units of Bupropion Hydrochloride extended release tablets manufactured by Ahemdabad-based Cadila Healthcare, the latest Enforcement Report of the USFDA has said.


    Bupropion Hydrochloride extended-release tablets, USP (XL) 300 mg are being recalled by Zydus Pharmaceuticals USA Inc on account of "Failed Dissolution Specifications: product did not meet dissolution specification at an intermediate time point", it added.


    The ongoing nationwide recall is a class III recall, it added.


    Bupropion hydrochloride extended-release tablets are indicated for the treatment of major depressive disorder.


    Sun Pharmaceutical Industries Inc, the US arm of drug major Sun Pharma is recalling 326,103 bottles of Kenalog (Triamcinolone Acetonide) spray with spray tube topical Aerosol on account of failed stability specifications. The class III ongoing recall of the product in the strength of 0.147 mg/g, 15 g bottle, that is a physician sample and not for sale is due to ,"low out of specification results for alcohol content," the report said.


    Kenalog spray is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.


    As per the United States Food and Drug Administration (USFDA), a class III recall is initiated in a "situation in which use of or exposure to a violative product is not likely to cause adverse health consequences".

    Bupropion HydrochlorideCadila HealthcareSun Pharmatriamcinolone acetonideUS Food & Drug AdministrationUSFDAzydus
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok